Safety update: dupilumab and ocular adverse reactions

Drug Ther Bull. 2023 Jan;61(1):6. doi: 10.1136/dtb.2022.000073.

Abstract

Overview of: Medicines and Healthcare products Regulatory Agency. Dupilumab (Dupixent▼): risk of ocular adverse reactions and need for prompt management. Drug Safety Update 2022;16(4): 1.

Keywords: Drug-Related Side Effects and Adverse Reactions; Health Care Quality, Access, and Evaluation.

MeSH terms

  • Antibodies, Monoclonal, Humanized* / adverse effects
  • Humans

Substances

  • dupilumab
  • Antibodies, Monoclonal, Humanized